The ongoing Phase III ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs. lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (MM) has been producing promising results thus far. In this interview, Keith Stewart, MD, ChB, of the Mayo Clinic, Scottsdale, AZ, discusses the updates on the trial that were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. These included updates on progression-free survival, as well as results for overall survival that were presented for the first time.
ASPIRE trial for MM: updates from ASH 2017
